Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
*Teva-discovered TEV-'408 targets IL-15, a key driver of vitiligo biology *TEV-'408 showed improvement in skin pigmentation and was wel
